New Drug To Treat Rheumatoid Arthritis

by Deepa Lakshmi on  August 24, 2018 at 7:36 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

New drug to treat rheumatoid arthritis was successful in Phase III clinical trial and the testing has been completed by an international research group led by Charité - Universitätsmedizin Berlin. This drug is effective in patients with moderate to severe disease condition who have shown less response to conventional disease modifying drugs. Results from this research have been published in The Lancet.
New Drug To Treat Rheumatoid Arthritis
New Drug To Treat Rheumatoid Arthritis

Rheumatoid arthritis is a painful inflammatory condition affecting the joints and tendons, which is typically characterized by periods of increased disease activity.

Prof. Dr. Gerd-Rüdiger Burmester, Head of Charité's Medical Department, Division of Rheumatology and Clinical Immunology, conducted a study to assess the efficacy of upadacitinib in patients with an inadequate response to 'conventional synthetic disease-modifying antirheumatic drugs'.

Upadacitinib is a selective inhibitor of the enzyme Janus kinase 1 (JAK1) and has been shown to be efficacious in this patient group in earlier phase II clinical trials.

By inhibiting JAK1, upadacitinib disrupts an important signaling pathway that is responsible for triggering inflammatory responses.

In the phase III study presented, patients treated with upadacitinib showed significant improvements in joint swelling when compared to patients receiving placebo.

Patients also experienced less pain and showed improvements in joint function. Prof. Burmester is very pleased to see this new tablet-based treatment produce such significant improvements in clinical symptoms.

"Our results prove that JAK inhibitors represent an effective treatment alternative in patients with long-term conditions who do not respond adequately to conventional drugs, and in those for whom biologics are not a good treatment option.

JAK inhibitors could help these patients achieve a quick response to treatment, allowing them to gain control over their illness.

The trial sponsor AbbVie is currently in the process of collating all trial results and submitting them to the European and US regulatory authorities for review."



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

Recommended Reading

More News on:

Drug Toxicity Osteoarthritis Rheumatoid Arthritis Clinical Trials - Different Phases of the trial Oligoarthritis Spondylolisthesis Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Knee Replacement 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive